7 giugno 2022 – Walder Wyss advises Gimv, a European investment company listed on Euronext Brussels partnering with entrepreneurial and innovative companies in forward-looking investment areas, as co-lead investor on the series B financing round of ImmunOs Therapeutics.

ImmunOs Therapeutics is a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases.

The proceeds will be used to fund the clinical development of ImmunOs’ lead program, IOS-1002 (formerly iosH2), through Phase 2 clinical trials and to progress additional oncology and autoimmune disease programs within the Company´s HLA-based pipeline towards clinical development.

The Walder Wyss team includes Alexander Gutmans (Partner, Corporate/M&A and Venture Capital) and Karina Tschon (Associate, Corporate/M&A and Venture Capital).